# Odyssey Therapeutics has raised $279 million in its upsized U.S. initial public offering.

*biotech · news · 2026-05-08 · MarketScreener*

## Key points

- Odyssey Therapeutics raised $279 million in its upsized U.S. IPO, selling 15.5 million shares at $18 each.
- The company’s IPO pricing exceeded its lower range, amid revived biotech listings in 2026.
- Odyssey’s lead drug candidate, OD-001 for ulcerative colitis, is in a mid-stage clinical trial.
- Founder Dr. Gary D. Glick also started Scorpion Therapeutics, acquired by Eli Lilly for $2.5 billion in 2025.
- IPO proceeds will primarily fund OD-001 clinical development and general corporate purposes.

**Companies:** Odyssey Therapeutics, Eli Lilly, Seaport Therapeutics, Hemab Therapeutics, Alamar Biosciences, Kailera Therapeutics, Scorpion Therapeutics
**Countries:** United States, Mexico

[Read the full story on MarketScreener](https://www.marketscreener.com/news/biotech-firm-odyssey-raises-279-million-in-upsized-us-ipo-ce7f5bdadf80fe22)

---

Canonical: https://newsio.io/n/5ae2885c-c83c-4ece-bab4-62e0351758ec/odyssey-therapeutics-has-raised-279-million-in-its-upsized-u-s-initial-public-of
Summarized by Newsio from MarketScreener. https://newsio.io/how-it-works